Table 3 Associations between biomarker levels and the change from baseline to weeks 24 and 102 in bone mineral density for patients in the infliximab group
Modelr2b*p Value
Spine BMD: % change from baseline to week 24
    Baseline biomarker levels, n = 144NSNSNS
    % change from baseline to week 2 in biomarker levels, n = 135NSNSNS
Spine BMD: % change from baseline to week 102
    Baseline biomarker levels, n = 1410.111
        Osteocalcin0.2540.019
    % change from baseline to week 2 in biomarker levels, n = 1320.174
        BAP0.1380.003
        CTX−0.0350.024
        VEGF−0.0810.046
Hip BMD: % change from baseline to week 24
    Baseline biomarker levels, n = 1430.153
        Osteocalcin0.0840.002
    % change from baseline to week 2 in biomarker levels, n = 1350.121
        BAP0.0270.019
        CTX−0.0080.038
Hip BMD: % change from baseline to week 102
    Baseline biomarker levels, n = 1410.237
        Osteocalcin0.172<0.0001
    % change from baseline to week 2 in biomarker levels, n = 1330.111
        BAP0.0380.039

  • BAP, bone alkaline phosphatase; BMD, bone mineral density; CTX, C-terminal cross-linking telopeptide of type I collagen; NS, not significant; VEGF, vascular endothelial growth factor.

  • *Represents the intercept value in the linear regression equation (y = mx+b).